RMD
Strong BuyPremium GrowerFLAGResMed Inc. · Healthcare · United States · $34.7B · Avg Vol: $335M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ResMed has exceptional quality Q86 with a buyback, but value V47 and momentum M38 are both below the calibrated floor, and insiders sold, so stage one fails.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT RESMED INC.
Read
ResMed Inc. is a global leader in medical devices and cloud-based software solutions for treating and managing sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its competitive moat is its innovative product portfolio, extensive patent protection, global distribution network, and leadership in connected health solutions that enhance patient adherence and outcomes. ResMed is a dominant player in sleep and respiratory care, benefiting from a growing addressable market and strong R&D.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 3.6B | 4.2B | 4.7B | 5.1B | 12.9% | 5.7B | 5.3B | 5.6B | 3.1% |
| EPS | 3.27 | 5.34 | 6.12 | 6.94 | 9.57 | 30.8% | 10.44 | 10.35 | 11.34 | 5.8% |
| Shares | — | 146.4M | 147.1M | 146.9M | 146.4M | -0.0% | 144.3M | — | — | — |
| Debt | — | 917.5M | 1.6B | 873.9M | 851.8M | -2.4% | 825.9M | — | — | — |
| Equity | — | 3.4B | 4.1B | 4.9B | 6.0B | 21.1% | — | — | — | — |
| Op CF | — | 351.1M | 693.3M | 1.4B | 1.8B | 70.9% | 1.8B | — | — | — |
| Inv CF | — | -229.9M | -1.2B | -269.8M | -200.0M | — | — | — | — | — |
| Fin CF | — | -128.4M | 422.9M | -1.1B | -606.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RMD | ResMed Inc.(you) | $34.7B | 87 | Strong Buy |
| BDX | Becton, Dickinson and Company | $51.6B | 77 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
Peer medians: ROE -31.5% · P/E 25.4x · Gross margin 58.1%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.